Illumina, Inc. (ILMN)
$
101.8
+2.51 (2.47%)
Key metrics
Financial statements
Free cash flow per share
6.5253
Market cap
15.6 Billion
Price to sales ratio
3.6523
Debt to equity
0.9666
Current ratio
1.8077
Income quality
1.2952
Average inventory
556 Million
ROE
0.5313
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, reflecting its robust operational framework. The earnings per share (EPS) is reported at -$7.69 indicating the company's profitability on a per-share basis, while the net total of other income and expenses is -$346,000,000.00 reflecting non-core financial activities. Operating expenses amount to $3,694,000,000.00 encompassing various operational costs incurred, and the total costs and expenses for the company are $5,205,000,000.00 reflecting its overall spending. Additionally, the weighted average number of shares outstanding is $159,000,000.00 highlighting the company's shareholder base and underscoring its financial health and stability. With a diverse range of products and services, Illumina serves a broad set of customers in genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical, biotechnology, and molecular diagnostics sectors. The company was incorporated in 1998 and is headquartered in San Diego, California, ensuring a strong presence in crucial markets. The stock is reasonably priced at $98.53 appealing to a broad range of investors looking for opportunities in the biotech field. Furthermore, the stock has a high average trading volume of $2,161,845.00 indicating strong liquidity and investor interest. With a mid-range market capitalization of $15,646,660,000.00 the company is a steady performer in the market. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape and driving advances in genetic analysis technologies. Additionally, it belongs to the Healthcare sector, which is experiencing rapid growth and innovation, positioning Illumina as a vital contributor to advancements in life sciences, oncology, and other emerging market segments.
Is Illumina, Inc. (ILMN) a good investment?
Investing in Illumina, Inc. (ILMN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Illumina, Inc. (ILMN)'s stock forecast?
Analysts predict Illumina, Inc. stock to fluctuate between $68.70 (low) and $156.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Illumina, Inc.'s market capitalization?
As of 2025-08-22, Illumina, Inc.'s market cap is $15,646,660,000, based on 153,700,000 outstanding shares.
How does Illumina, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Illumina, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Illumina, Inc. (ILMN) stock?
To buy Illumina, Inc. (ILMN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ILMN. Place an order (Market, Limit, etc.).
What is the best time to invest in Illumina, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Illumina, Inc. stock ever split?
Illumina, Inc.'s last stock split was 2:1 on 2008-09-23.
How did Illumina, Inc. perform in the last earnings report?
Revenue: $4,372,000,000 | EPS: -$7.69 | Growth: 4.63%.
Where can I find Illumina, Inc.'s investor relations reports?
Visit https://www.illumina.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Illumina, Inc.?
You can explore historical data from here
What is the all-time high and low for Illumina, Inc. stock?
All-time high: $526 (2021-08-16) | All-time low: $68.70 (2025-04-09).
What are the key trends affecting Illumina, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into proteomics with the SomaLogic acquisition and new single-cell CRISPR offerings, aiming for high future revenue growth. Despite ongoing headwinds from China restrictions and US academic funding cuts, Illumina's cost-cutting and divestments have improved profitability and cash flow.
seekingalpha.com
Illumina, Inc. (NASDAQ:ILMN ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Interim Head of Investor Relations Jacob Thaysen - CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Eve Burstein - Sanford C. Bernstein & Co., LLC.
zacks.com
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Illumina (ILMN) came out with quarterly earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.36 per share a year ago.
seekingalpha.com
With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina. Illumina has reported higher gross profit margins than its peers, which reflects that its core business is profitable.
prnewswire.com
Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recognizing the company's leadership in sustainability practices and as an employer of choice. TIME named Illumina to its World's Most Sustainable Companies list for the second year in a row, and U.S. News & World Report named Illumina to its Best Companies to Work For list.
zacks.com
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
prnewswire.com
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO , June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. "The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.
zacks.com
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
See all news
